AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Mothers against decapentaplegic homolog 7

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O15105

UPID:

SMAD7_HUMAN

Alternative names:

Mothers against decapentaplegic homolog 8; SMAD family member 7

Alternative UPACC:

O15105; B7Z773; K7EQ10; O14740; Q6DK23

Background:

Mothers against decapentaplegic homolog 7 (SMAD7), also known as SMAD family member 7, plays a pivotal role in cellular processes by acting as an antagonist of TGF-beta signaling. It inhibits TGF-beta and activin signaling pathways by associating with their receptors, thus blocking SMAD2 access. SMAD7 also recruits SMURF2 to the TGF-beta receptor complex and the PPP1R15A-PP1 complex to TGFBR1, enhancing dephosphorylation and positively regulating PDPK1 kinase activity.

Therapeutic significance:

Given its crucial role in modulating TGF-beta signaling, SMAD7 is directly linked to the pathogenesis of Colorectal cancer 3. Its involvement suggests that targeting SMAD7 could offer a novel therapeutic approach for managing colorectal cancer, particularly in cases where genetic susceptibility is influenced by variants affecting this gene.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.